Date: 2015-09-29
Type of information: Financing round
Company: Oncobiologics (USA - NJ)
Investors: Sabby Management (USA - NJ) Perceptive Advisors (USA - NY) Cormorant Global Healthcare Master Fund (USA - MA) Longwood Capital Partners (USA - CA) Venbio Select Fund (USA - CA)
Amount: $44 million
Funding type: financing round
Planned used: Net proceeds of the financing will be used to support planned expansion of Oncobiologics’s facility as well as continued development and expansion of the company’s proprietary BioSymphony™ Platform and advancement of its preclinical and clinical monoclonal antibody biosimilar programs.
Others: * On September 29, 2015, Oncobiologics announced that it closed an additional round of financing with Sabby Management, LLC. This equity financing, along with the prior investment round that was announced in July 2015, generated aggregate gross proceeds of approximately $44 million. Several investors from the initial closing also participated in the extension of the initial round. Sabby joins the existing institutional investors supporting Oncobiologics, which includePerceptive Advisors, Cormorant Global Healthcare Master Fund, Longwood Capital Partners and Venbio Select Fund. Citigroup and Jefferies LLC advised Oncobiologics on the transactions.
Therapeutic area:
